Addressing Climate Change

There are more than 5 trillion pieces of plastic floating in our oceans. The U.S. transportation sector leads all other sectors in greenhouse gas emissions. Diseases that thrive in hot weather are killing important staple crops. Our reliance on products derived from fossil fuels is harming our planet.

Climate change is real but through biotechnology, we can meet these challenges head-on by making the same reliable plastics, foods, and fuels with less environmental impact.

Press Releases
December 12, 2022
VANCOUVER, BC, CANADA, and WASHINGTON, DC, UNITED STATES, Dec. 12, 2022 – Today, Novateur Ventures, a leading global life sciences advisory firm and Biotechnology Innovation Organization (BIO), the world's largest advocacy association for biosciences, research and academic institutions, launched an…
November 15, 2022
The next farm bill offers an opportunity to examine innovation’s influence on the resiliency of our economy in the face of global challenges, BIO wrote in a statement for the record to the Senate Agriculture Committee's Nov. 15 hearing on energy and rural development programs in the 2023 farm bill,…
November 14, 2022
The Biotechnology Innovation Organization (BIO) is pleased to announce that Beth Ellikidis has joined BIO as Vice President, Agriculture and Environment. In her role, Beth will lead the policy and market access strategies for BIO’s Agriculture and Environment section, which includes member…
Good Day BIO Newsletter
Subscribe to GoodDay BIO

Receive the best resource for the biotech industry with Good Day BIO, the only daily newsletter at the intersection of biotech, politics and policy. 

Letters, Comments & Testimony
September 24, 2022
BIO and its members appreciate the opportunity to work with FDA to develop and align on approaches that are robust, practical, and expedite patient focused drug development. To further enhance the Guidance, we believe that a few areas would benefit from more explanation, examples, and references…
June 22, 2022
On Wednesday, June 22nd, BIO submitted comments on the FDA’s Quality Metrics (QM) Reporting Program. In the comments submitted, BIO stated appreciation for FDA’s intent to support a general shift toward a risk-based approach to regulation by bolstering its quality surveillance activities. However,…
September 28, 2022
On Wednesday, September 28th, BIO submitted comments to the Food & Drug Administration on the ICH Q2(R2) Guideline: Validation of Analytical Procedures and the ICH Q14 Guideline: Analytical Procedure Development. In addition to a number of specific line edits, BIO suggested broadly that the ICH…